title: Reversible dysphasia and statins.
abstract: This paper presents a case of reversible dysphasia occurring in a patient prescribed atorvastatin in combination with indapamide. A milder dysphasia recurred with the prescription of rosuvastatin and was documented on clinical examination. This resolved following cessation of rosuvastatin. The case highlights both a need for a wider understanding of potential drug interactions through the CYP 450 system and for an increased awareness, questioning and reporting of drug side-effects.
authors.affiliation: Department of Psychiatry, University of Wollongong, New South Wales, Australia. alienist@ihug.com.au
authors.forename: Gordon Robert Wyndham
authors.initials: GR
authors.lastname: Davies
mesh_terms: D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001007:Anxiety / Q000175:diagnosis; D001037:Aphasia / Q000175:diagnosis / Q000209:etiology*; D000069059:Atorvastatin; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D003863:Depression / Q000175:diagnosis; D004347:Drug Interactions; D005260:Female; D005464:Fluorobenzenes / Q000009:adverse effects / Q000627:therapeutic use*; D006538:Heptanoic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D007190:Indapamide / Q000627:therapeutic use; D008875:Middle Aged; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D005464:Fluorobenzenes; D006538:Heptanoic Acids; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D003577:Cytochrome P-450 Enzyme System; D000069059:Atorvastatin; D007190:Indapamide